Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
The approval granted last week is supported by the first phase of the Phase 3 ESSENCE trial where 37 per cent of patients on a 2.4 mg demonstrated improvement in liver fibrosis (scarring) without worsening steatohepatitis (fat buildup) after 72 weeks of treatment, compared to 22.5 per cent on placebo
Specifically, GLP-1 use was associated with an 18% lower risk of a composite TED-related diagnosis at one year and a 10% lower risk at three years. This retrospective, population-based cohort study used the TriNetX US Collaborative Network to identify patients with thyroid disease initiating a GLP-1 drug or a non-GLP-1 active control medication
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimers disease
Research by Roh et al
S kt hp ny khng ch gip trng da , xa vt thm sm trn da , gim thm nm m cn mang li hiu qu lu di trong vic chm sc da v bo v sc khe ton din
